tisotumab vedotin (Rx)

Brand and Other Names:Tivdak, tisotumab vedotin-tftv
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, lyophilized powder for reconstitution

  • 40mg/vial

Cervical Cancer

Indicated for recurrent or metastatic cervical cancer in patients with disease progression during or following chemotherapy

2 mg/kg IV q3Weeks; not to exceed 200 mg/dose for patients ≥100 kg  

Continue until disease progression or unacceptable toxicity

Refer to Dosing Considerations for premedication and required eye care

Dosage Modifications

Dose reduction schedule

  • First reduction: 1.3 mg/kg
  • Second reduction: 0.9 mg/kg
  • Permanently discontinue if unable to tolerate 0.9 mg/kg

Keratitis

  • Superficial punctate keratitis (SPK), any occurrence: Monitor
  • Ulcerative keratitis or perforation: Permanently discontinue
  • Confluent superficial keratitis
    • First occurrence: Withhold until SPK or normal, then resume at next lower dose
    • Second occurrence: Permanently discontinue

Conjunctival ulceration

  • First occurrence: Withhold until complete conjunctival reepithelialization; resume at next lower dose
  • Second occurrence: Permanently discontinue

Conjunctival or corneal scarring or symblepharon

  • Any scarring or symblepharon: Permanently discontinue

Conjunctivitis and other ocular adverse reactions

  • Grade 1, any occurrence: Monitor
  • Grade 2-4
    • Grade 2, first occurrence: Withhold until Grade ≤1; resume at same dose
    • Grade 2, second occurrence: Withhold until Grade ≤1, then resume at next lower dose; if no resolution to Grade ≤1, permanently discontinue
    • Grade 2, third occurrence: Permanently discontinue
    • Grade 3 or 4: Permanently discontinue

Peripheral neuropathy

  • Grade 2, initial or worsening of preexisting condition: Withhold until Grade ≤1; resume at next lower dose
  • Grade 3 or 4: Permanently discontinue

Hemorrhage

  • Any grade pulmonary or CNS: Permanently discontinue
  • Any other location
    • Grade 2: Withhold until resolved; resume at same dose
    • Grade 3, first occurrence: Withhold until resolved; resume at same dose
    • Grade 3, second occurrence or grade 4: Permanently discontinue

Pneumonitis

  • Grade 2: Withhold until Grade ≤1 for persistent or recurrent pneumonitis; consider resuming at next lower dose
  • Grade 3 or 4: Permanently discontinue

Renal impairment

  • CrCl 30 to <90 mL/min: No dosage adjustment required
  • CrCl 15 to <30 mL/min or end-stage renal disease (ESRD) with or without dialysis: Pharmacokinetics unknown

Hepatic impairment

  • Mild (total bilirubin [TB] ≤ULN and AST >ULN or TB >1 to 1.5x ULN and any AST): Closely monitor for adverse effects; no dosage adjustment for starting dose
  • Moderate-to-severe (TB >1.5x ULN): Avoid use

Dosing Considerations

Verify pregnancy status in females of reproductive potential before initiating

Premedication and required eye care

  • Ophthalmic examination: Conduct ophthalmic examination including visual acuity and slit-lamp examination at baseline, before each dose, and as clinically indicated
  • Topical corticosteroid eye drops: Determine initial prescription and all renewals of any corticosteroid medication only after examination with a slit-lamp; administer first drop in each eye before to each infusion and instruct patients to continue administration in each eye for 72 hr after each infusion
  • Topical ocular vasoconstrictor drops: Administer in each eye immediately before each infusion
  • Cold-packs: Use cooling eye pads during IV infusion
  • Topical lubricating ophthalmic drops: Instruct patients to administer for duration of therapy and for 30 days after last dose
  • Contact lenses: Advise patients to avoid wearing contact lenses unless advised by their eye care provider for the entire duration of therapy

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and tisotumab vedotin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (26)

                • abametapir

                  abametapir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • atazanavir

                  atazanavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • chloramphenicol

                  chloramphenicol increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • clarithromycin

                  clarithromycin increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • cobicistat

                  cobicistat increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • conivaptan

                  conivaptan increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • darunavir

                  darunavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • elvitegravir/cobicistat/emtricitabine/tenofovir DF

                  elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • grapefruit

                  grapefruit increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • idelalisib

                  idelalisib increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • indinavir

                  indinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • isoniazid

                  isoniazid increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • itraconazole

                  itraconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • ketoconazole

                  ketoconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • lonafarnib

                  lonafarnib increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • lopinavir

                  lopinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • mifepristone

                  mifepristone increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • nefazodone

                  nefazodone increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • nelfinavir

                  nelfinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • posaconazole

                  posaconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • ritonavir

                  ritonavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • rucaparib

                  rucaparib increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • saquinavir

                  saquinavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • stiripentol

                  stiripentol increases and tisotumab vedotin decreases affecting hepatic/intestinal enzyme CYP3A4 metabolism. Effect of interaction is not clear, use caution. Use Caution/Monitor. Stiripentol is both an inibitor and inducer of CYP3A4. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects. .

                • tipranavir

                  tipranavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                • voriconazole

                  voriconazole increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects.

                Minor (0)

                  Previous
                  Next:

                  Adverse Effects

                  >10%

                  All grades

                  • Fatigue (50%)
                  • Nausea (41%)
                  • Peripheral neuropathy (39%)
                  • Alopecia (39%)
                  • Epistaxis (39%)
                  • Conjunctival adverse reactions (37%)
                  • Hemorrhage (32%)
                  • Dry eye (29%)
                  • Rash (25%)
                  • Diarrhea (25%)
                  • Constipation (23%)
                  • Abdominal pain (23%)
                  • Corneal adverse reactions (21%)
                  • Myalgia (21%)
                  • Vomiting (17%)
                  • Periorbital adverse reactions (16%)
                  • Pyrexia (16%)
                  • Arthralgia (16%)
                  • Decreased appetite (16%)
                  • Urinary tract infection (14%)
                  • Pain in extremity (13%)
                  • Pruritus (13%)
                  • Decreased weight (12%)

                  Laboratory abnormalities (all grades)

                  • Hemoglobin decreased (52%)
                  • Lymphocytes decreased (42%)
                  • Leukocytes decreased (30%)
                  • Creatinine increased (29%)
                  • Prothrombin INR increased (26%)
                  • aPTT prolonged (26%)
                  • ALT increased (24%)
                  • Lactate dehydrogenase increased (22%)
                  • Neutrophils decreased (21%)
                  • Urate increased (20%)
                  • Sodium decreased (20%)
                  • Glucose decreased (19%)
                  • AST increased (18%)
                  • Alkaline phosphatase increased (17%)
                  • Magnesium decreased (17%)
                  • Creatinine kinase increased (16%)
                  • Albumin decreased (16%)

                  1-10%

                  All grades

                  • Fatigue (7%)
                  • Peripheral neuropathy (7%)
                  • Hemorrhage (6%)
                  • Corneal adverse reactions (3%)
                  • Diarrhea (2%)
                  • Constipation (2%)
                  • Vomiting (2%)
                  • Urinary tract infection (2%)
                  • Pain in extremity (1%)
                  • Decreased appetite (1%)
                  • Abdominal pain (1%)
                  • Pyrexia (1%)
                  • Pruritus (1%)

                  Laboratory abnormalities (grade 3-4)

                  • Lymphocytes decreased (8%)
                  • Hemoglobin decreased (7%)
                  • Creatinine increased (4.1%)
                  • Neutrophils decreased (3%)
                  • Creatinine kinase increased (2.1%)
                  • Magnesium decreased (2.1%)
                  • aPTT prolonged (2%)
                  Previous
                  Next:

                  Warnings

                  Black Box Warnings

                  Ocular toxicity

                  • Causes changes in corneal epithelium and conjunctiva resulting in vision changes, including severe vision loss, and corneal ulceration
                  • Conduct ophthalmic examination at baseline, prior to each dose, and as clinically indicated
                  • Adhere to premedication and required eye care before, during, and after infusion
                  • Withhold until improvement and resume, reduce the dose, or permanently discontinue, based on severity

                  Contraindications

                  None

                  Cautions

                  Based on mechanism of action and findings in animal studies, can cause fetal harm

                  Peripheral neuropathy

                  • Peripheral neuropathy reported
                  • Median time to onset of peripheral neuropathy reported to be 2.4 months (range, 0-11.3 months)
                  • Monitor for signs and symptoms of neuropathy (eg, paresthesia, tingling or burning sensation, neuropathic pain, muscle weakness, dysesthesia)
                  • If observed, withhold dose, then reduce dose or permanently discontinue

                  Hemorrhage

                  • Hemorrhage occurred in a majority of treated patients
                  • Median time to onset of hemorrhage reported to be 0.3 months (range, 0-6.5 months)
                  • Monitor and withhold or discontinue dose as recommended

                  Pneumonitis

                  • Severe, life-threatening, or fatal pneumonitis can occur in patients treated with antibody-drug conjugates
                  • Pulmonary symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic examinations; infectious, neoplastic, and other causes for such symptoms should be excluded through appropriate investigations
                  • Monitor for pulmonary symptoms and adjust dose, withhold treatment, or permanently discontinue as recommended

                  Ocular adverse effects

                  • Ocular adverse reactions reported; promptly refer patients to an eye care provider for any new or worsening ocular signs and symptoms
                  • Conduct ophthalmic examination including visual acuity and slit lamp examination at baseline, before each dose, and as clinically indicated
                  • Administer premedication and cold-pack regimen with each infusion
                  • Common ocular adverse reactions included conjunctival adverse reactions (40%), dry eye (29%), corneal adverse reactions (21%), and blepharitis (8%)
                  • Grade 3 ocular adverse reactions occurred in 3.8%, including severe ulcerative keratitis in 3.2% of patients
                  • One patient experienced ulcerative keratitis with perforation requiring corneal transplantation
                  • Symblepharon was reported in patients with other tumor types treated at the recommended dose
                  • Median time to onset of first ocular adverse reaction was 1.2 months
                  • Among patients who experienced ocular events, 55% had complete resolution, 30% had partial improvement, 6% discontinued treatment

                  Drug interaction overview

                  • Strong CYP3A4 inhibitors
                    • Monitor closely if coadministered
                    • Tisotumab vedotin is metabolized to monomethyl auristatin E (MMAE), a mitotic inhibitor and the cytotoxic component of the antibody-drug conjugate
                    • MMAE is substrate of CYP3A4
                    • Strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects
                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy

                  Based on mechanism of action and findings in animals, can cause fetal harm when administered to pregnant females

                  Human data are not available to evaluate drug-associated risk

                  Advise patients of potential risk to fetus and verify pregnancy status in females of reproductive potential before initiating

                  Animal studies

                  • Administration of MMAE (tisotumab vedotin active metabolite) to pregnant rats during organogenesis caused embryofetal mortality and structural abnormalities at exposures below the clinical exposure at the recommended dose

                  Contraception

                  • Females of reproductive potential: Use effective contraception during treatment and for 2 months after last dose
                  • Males with female partners of reproductive potential: Use effective contraception during treatment and for 4 months after last dose

                  Infertility

                  • Males: Based on findings from animal studies, may impair fertility

                  Lactation

                  Data are not available on presence in human milk, effects on breastfed children, or effects on milk production

                  Advise lactating females not to breastfeed during treatment and for 3 weeks after last dose

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Antibody-drug conjugate composed of a monoclonal antibody against human tissue factor that is covalently bound by a protease-cleavable peptide liner to monomethyl auristatin E (MMAE), an auristatin derivative

                  MMAE is an agent that disrupts microtubules; disruption of the microtubule network of actively dividing cells leads to cell cycle arrest and apoptotic cell death

                  Absorption

                  Peak plasma concentration: 40.8 mcg/mL; 5.91 ng/mL (unconjugated MMAE)

                  AUC: 57.5 day⋅mcg/mL; 50 day⋅ng/mL (unconjugated MMAE)

                  Vd: 7.83 L

                  Distribution

                  Protein bound: 68-82% (MMAE)

                  Metabolism

                  Tisotumab vedotin undergoes catabolism to small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE-related catabolites

                  Unconjugated MMAE primarily metabolized by CYP3A4 (in vitro)

                  Elimination

                  Half-life: 4.04 days; 2.56 days (unconjugated MMAE)

                  Clearance: 1.54 L/day; 45.9 L/day (unconjugated MMAE)

                  Excretion (MMAE): 17% feces; 6% urine over 1 week

                  Previous
                  Next:

                  Administration

                  IV Incompatibilities

                  Do not mix with or administer with other medicinal products

                  IV Compatibilities

                  D5W

                  NaCl 0.9%

                  Lactated Ringer solution

                  IV Preparation

                  Follow applicable special handling and disposal procedures for hazardous drugs

                  Reconstitute lyophilized powder

                  • Calculate dose according to patient’s weight and determine number of single-dose vials needed
                  • Reconstitute each 40-mg vial with 4 mL sterile water for injection; resulting concentration is 10 mg/mL
                  • Slowly swirl each vial until contents are completely dissolved; allow reconstituted vial(s) to settle; do NOT shake vial or expose to direct sunlight
                  • Inspect visually for particulate matter and discoloration; reconstituted solution should appear clear to slightly opalescent, colorless to brownish-yellow, and free of visible particles; discard if visible particles or discoloration observed
                  • Add calculated dose from vial(s) to infusion bag immediately; if not used immediately, see storage recommendations below

                  Dilution in infusion bag

                  • Dilute with D5W, NaCl 0.9%, or Lactated Ringer solution in infusion bag to achieve final concentration of 0.7-2.4 mg/mL
                  • Mix diluted solution by gentle inversion; do NOT shake bag or expose to direct sunlight
                  • Visually inspect for any particulate matter or discoloration; discard if particulate matter or discoloration observed
                  • Discard any unused portion left in vials

                  IV Administration

                  For IV infusion only; do NOT administer as IV push or bolus

                  Confirm administration of steroid and vasoconstrictor ophthalmic drops

                  Apply cold packs fully over eyes following administration of the vasoconstrictor eye drops and leave on during IV infusion; change cold packs as needed throughout infusion to ensure eye area remains cold

                  Immediately administer IV infusion over 30 minutes via IV line containing a 0.2-μm inline filter

                  If infusion not administered immediately, store diluted solution in refrigeration as specified in storage below

                  Storage

                  Does not contain preservatives

                  Do NOT freeze or expose to direct sunlight

                  Do not shake vials

                  Unopened vial

                  • Refrigerate at 2-8ºC (36-46ºF) in original carton to protect from light

                  Reconstituted vial

                  • Refrigerate at 2-8ºC (36-46ºF) for up to 24 hr, OR
                  • Store at room temperature up to 25ºC (77ºF) for maximum of 8 hr before dilution

                  Diluted infusion bag

                  • Refrigerate at 2-8ºC (36-46ºF)
                  • Duration of refrigeration depends on solution
                    • Lactated Ringer solution: Up to 12 hr
                    • 0.9% NaCl: Up to 18 hr
                    • D5W: Up to 24 hr
                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  Additional Offers
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.